Milestones

2019

ChromoTek launches Nano-Secondaries: monoclonal recombinant Nanobodies to bind with high specificity and affinity to rabbit and mouse primary antibodies in a subtype specific manner.

2018

ChromoTek launches the Spot-capture and detection system for universal applications: This is the first peptide-tag and Nanobody used in super resolution microscopy. The inert Spot-Tag® and Nanobody can also applied in immunoprecipitation, purification, Western blotting and immunofluorescence.

2016

Highest number of literature references establishes GFP-Trap® as the gold standard for immunoprecipitation of GFP-fusion proteins and their interacting partners.

2014

  • ChromoTek opens a subsidiary on East Coast to strengthens its customers’ support in the US.
  • ChromoTek’s Fluorescent 2-Hybrid (F2H®) technology enables screening and validation of compounds in living cells.

2013

  • ChromoTek licenses Chromobody® technology for high content drug profiling to Bayer
  • ChromoTek introduces Chromobody plasmids for real time monitoring of key intracellular target molecules in vivo.

2011

ChromoTek moves into IZB in Martinsried

2010

ChromoTek introduces Nano-Boosters and Nano-Labels: fluorescently labeled Nanobodies for advanced immunofluorescence.

2008

  • ChromoTek launches GFP-Trap, the worldwide first Nanobody-based reagent for immunoprecipitation of fluorescent proteins
  • ChromoTek starts to pioneer the use of Nanobodies for research applications
  • Foundation of ChromoTek GmbH in Munich, Germany